{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:50:00Z","timestamp":1792511400481,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 AR073208"],"award-info":[{"award-number":["RO1 AR073208"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.xjidi.2026.100460","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:29:09Z","timestamp":1771028949000},"page":"100460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoantibodies as biomarkers of cancer risk in dermatomyositis"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1319-3318","authenticated-orcid":false,"given":"Christina E.","family":"Bax","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-1539","authenticated-orcid":false,"given":"Livia","family":"Casciola-Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7951-3674","authenticated-orcid":false,"given":"David","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100460_bib1","first-page":"1300","article-title":"Elevated cancer incidence in patients with dermatomyositis: a population based study","volume":"22","author":"Airio","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib2","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2340\/00015555-3091","article-title":"Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis","volume":"99","author":"Best","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.xjidi.2026.100460_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.xjidi.2026.100460_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","article-title":"Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study","volume":"134","author":"Buchbinder","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.xjidi.2026.100460_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1186\/s13075-014-0428-x","article-title":"Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study","volume":"16","author":"Chang","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2026.100460_bib6","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2026.100460_bib7","first-page":"9","article-title":"Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark","volume":"6","author":"Chow","year":"1995","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.xjidi.2026.100460_bib8","series-title":"Autoimmunity: from bench to bedside [Internet]","article-title":"Autoimmune diseases and cancer","author":"Ehrenfeld","year":"2013"},{"key":"10.1016\/j.xjidi.2026.100460_bib9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/art.42474","article-title":"Association of anti-CCAR1 autoantibodies with decreased cancer risk relative to the general population in patients with anti-transcriptional intermediary factor 1\u03b3-positive dermatomyositis","volume":"75","author":"Fiorentino","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib10","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xjidi.2026.100460_bib11","first-page":"1048","article-title":"Distinct dermatomyositis populations are detected with different autoantibody assay platforms","volume":"37","author":"Fiorentino","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.xjidi.2026.100460_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"Fujimoto","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xjidi.2026.100460_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103375","article-title":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","volume":"22","author":"Guerra","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.xjidi.2026.100460_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-024-01171-8","article-title":"Newer autoantibodies and laboratory assessments in myositis","volume":"27","author":"Harvey","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.xjidi.2026.100460_bib17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.xjidi.2026.100460_bib18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2026.100460_bib19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/j.1365-2133.2009.09274.x","article-title":"Malignancies associated with dermatomyositis and polymyositis in Taiwan: a nationwide population-based study","volume":"161","author":"Huang","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/1346-8138.15284","article-title":"Clinical significance of serum levels of anti-transcriptional intermediary factor 1-\u03b3 antibody in patients with dermatomyositis","volume":"47","author":"Ikeda","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1126\/science.1246886","article-title":"Association of the autoimmune disease scleroderma with an immunologic response to cancer","volume":"343","author":"Joseph","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xjidi.2026.100460_bib22","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/rheumatology\/keae167","article-title":"Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort","volume":"63","author":"Loganathan","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2026.100460_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/BOR.0000000000001039","article-title":"Autoantibody testing in myositis: an update","volume":"36","author":"McMorrow","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib25","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/art.42311","article-title":"Subsets of idiopathic inflammatory myositis enriched for contemporaneous cancer relative to the general population","volume":"75","author":"Mecoli","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.15526","article-title":"Clinical features of anti-transcription intermediary factor 1\u03b3 (TIF1\u03b3)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1\u03b3 expression in tumors in the pathogenesis of cancer-associated dermatomyositis","volume":"47","author":"Motegi","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.804037","article-title":"A commercial anti-TIF1\u03b3 ELISA is superior to line and dot blot and should be considered as part of routine myositis-specific antibody testing","volume":"13","author":"Mulhearn","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100460_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-018-1617-9","article-title":"Genetic background may contribute to the latitude-dependent prevalence of dermatomyositis and anti-TIF1-\u03b3 autoantibodies in adult patients with myositis","volume":"20","author":"Parkes","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2026.100460_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2026.100460_bib31","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1203475416665601","article-title":"Risk of malignancy in dermatomyositis and polymyositis","volume":"21","author":"Qiang","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.xjidi.2026.100460_bib32","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.xjidi.2026.100460_bib33","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/rheumatology\/keac288","article-title":"ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis","volume":"61","author":"Selickaja","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2026.100460_bib34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/art.38928","article-title":"Review: cancer-induced autoimmunity in the rheumatic diseases","volume":"67","author":"Shah","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/1346-8138.15128","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody as a biomarker in patients with dermatomyositis","volume":"47","author":"Shimizu","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM199202063260602","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study","volume":"326","author":"Sigurgeirsson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xjidi.2026.100460_bib37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1054\/bjoc.2001.1699","article-title":"Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study","volume":"85","author":"Stockton","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.xjidi.2026.100460_bib38","article-title":"Cell-free DNA profiles of dermatomyositis and its potential role in discriminating phenotypes","volume":"16","author":"Tang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.xjidi.2026.100460_bib39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","article-title":"The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis","volume":"22","author":"Tansley","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.xjidi.2026.100460_bib40","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.xjidi.2026.100460_bib41","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s10067-018-4216-x","article-title":"Calcinosis and malignancy are rare in Chinese adult patients with myositis and nuclear matrix protein 2 antibodies identified by an unlabeled immunoprecipitation assay","volume":"37","author":"Wang","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.xjidi.2026.100460_bib42","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/rheumatology\/keae425","article-title":"Circulating cell-free DNA promotes inflammation in dermatomyositis patients with anti-NXP2 antibodies via the cGAS\/STING pathway","volume":"64","author":"Wang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.xjidi.2026.100460_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.750533","article-title":"Six autoimmune disorders are associated with increased incidence of gastric cancer: a systematic review and meta-analysis of half a million patients","volume":"12","author":"Z\u00e1dori","year":"2021","journal-title":"Front Immunol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:12:54Z","timestamp":1779196374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2667026726000123"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100460","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies as biomarkers of cancer risk in dermatomyositis","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100460"}}